[S02DA03, antipyrine, Antipyrine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01GA01, streptomycin, Gabapentin enacarbil may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Gabapentin enacarbil.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01CG01, sulbactam, Gabapentin enacarbil may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, Sulfadiazine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01EC01, sulfamethoxazole, Sulfamethoxazole may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M01AB02, sulindac, Sulindac may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Sulpiride is combined with Gabapentin enacarbil.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Sulthiame is combined with Gabapentin enacarbil.]
[M01AX04, apazone, Azapropazone may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Gabapentin enacarbil.]
[R03CC03, terbutaline, Terbutaline may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, Dabigatran etexilate may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[G03BA03, testosterone, Testosterone may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Tetracaine.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Lurasidone is combined with Gabapentin enacarbil.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Gabapentin enacarbil.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Gabapentin enacarbil.]
[L04AX02, thalidomide, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Gabapentin enacarbil.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Thiopental is combined with Gabapentin enacarbil.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Thioproperazine is combined with Gabapentin enacarbil.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Thioridazine is combined with Gabapentin enacarbil.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Thiothixene is combined with Gabapentin enacarbil.]
[G04BE06, moxisylyte, Gabapentin enacarbil may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Tiapride.]
[B01AC05, ticlopidine, Ticlopidine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Tilidine.]
[S01ED01, timolol, Timolol may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[S01AA12, tobramycin, Gabapentin enacarbil may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Tolazamide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[V04CA01, tolbutamide, Tolbutamide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M02AA21, tolmetin, Tolmetin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Tolperisone is combined with Gabapentin enacarbil.]
[N02AX02, tramadol, The risk or severity of CNS depression can be increased when Gabapentin enacarbil is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Gabapentin enacarbil.]
[N06AX05, trazodone, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Trazodone.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Gabapentin enacarbil.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB12, mepenzolate, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[A16AX12, trientine, Triethylenetetramine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Gabapentin enacarbil.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Trifluperidol.]
[N05AA05, triflupromazine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Alimemazine is combined with Gabapentin enacarbil.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Gabapentin enacarbil.]
[J01EA01, trimethoprim, Trimethoprim may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N06AA06, trimipramine, The risk or severity of adverse effects can be increased when Trimipramine is combined with Gabapentin enacarbil.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Gabapentin enacarbil.]
[A03BB01, butylscopolamine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Vilazodone is combined with Gabapentin enacarbil.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Gabapentin enacarbil.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Tubocurarine is combined with Gabapentin enacarbil.]
[R03DX07, roflumilast, Roflumilast may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[L01FX04, ipilimumab, Ipilimumab may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[R02AA14, oxyquinoline, Gabapentin enacarbil may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[S01AA28, vancomycin, Gabapentin enacarbil may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Ezogabine is combined with Gabapentin enacarbil.]
[B01AF01, rivaroxaban, Rivaroxaban may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C08DA01, verapamil, Verapamil may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N06AX09, viloxazine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Viloxazine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[B01AA03, warfarin, Gabapentin enacarbil may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Gabapentin enacarbil.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Levetiracetam is combined with Gabapentin enacarbil.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M05BA05, tiludronic acid, Tiludronic acid may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[B06AC02, icatibant, Icatibant may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Deferiprone may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[L01EJ01, ruxolitinib, Gabapentin enacarbil may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[J01DH04, doripenem, Doripenem may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Atracurium.]
[S01FA01, atropine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[B03XA04, peginesatide, Gabapentin enacarbil may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Azacitidine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[L04AX01, azathioprine, Azathioprine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Gabapentin enacarbil.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Lorcaserin is combined with Gabapentin enacarbil.]
[G04BD12, mirabegron, Gabapentin enacarbil may decrease the excretion rate of Mirabegron which could result in a higher serum level.]
[L02BB04, enzalutamide, Gabapentin enacarbil may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[A02AA05, magnesium silicate, The serum concentration of Gabapentin enacarbil can be decreased when it is combined with Magnesium silicate.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Barbital is combined with Gabapentin enacarbil.]
[D02BA02, octinoxate, Gabapentin enacarbil may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin enacarbil.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Rasagiline is combined with Gabapentin enacarbil.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Gabapentin enacarbil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Gabapentin enacarbil.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Gabapentin enacarbil.]
[R06AC06, thonzylamine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Gabapentin enacarbil may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Diethyl ether.]
[V08CA11, gadofosveset, Gadofosveset trisodium may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[A16AX08, teduglutide, Gabapentin enacarbil may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[A10BH04, alogliptin, Alogliptin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, Gabapentin enacarbil may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Pomalidomide.]
[N02BA10, benorilate, Benorilate may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Benperidol.]
[A10BK02, canagliflozin, Canagliflozin may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Benzocaine is combined with Gabapentin enacarbil.]
[L03AA12, ancestim, Gabapentin enacarbil may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, Celecoxib may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Gabapentin enacarbil.]
[N04AC01, benztropine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[R02AX03, benzydamine, Benzydamine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[L01EE01, trametinib, Gabapentin enacarbil may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Gabapentin enacarbil.]
[V09AX05, florbetapir F-18, Gabapentin enacarbil may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Levomilnacipran.]
[A10BJ03, lixisenatide, Gabapentin enacarbil may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, Gabapentin enacarbil may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Vortioxetine.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Eslicarbazepine.]
[J05AP08, sofosbuvir, Gabapentin enacarbil may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Gabapentin enacarbil.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, Droxidopa may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Tasimelteon.]
[L04AA32, apremilast, Apremilast may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[L02BG02, formestane, Gabapentin enacarbil may decrease the excretion rate of Formestane which could result in a higher serum level.]
[A16AA06, betaine, The therapeutic efficacy of Betaine can be decreased when used in combination with Gabapentin enacarbil.]
[V03AB34, fomepizole, Fomepizole may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[A03BA03, hyoscyamine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Alfaxalone.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[D11AA01, glycopyrronium, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05CM19, suvorexant, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Acepromazine is combined with Gabapentin enacarbil.]
[N04AA02, biperiden, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[S03AA06, gentamicin, Gabapentin enacarbil may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[B01AF03, edoxaban, Gabapentin enacarbil may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[A03AA09, difemerine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Flibanserin is combined with Gabapentin enacarbil.]
[A06AD03, magnesium peroxide, The serum concentration of Gabapentin enacarbil can be decreased when it is combined with Magnesium peroxide.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Cariprazine is combined with Gabapentin enacarbil.]
[M02AA25, aceclofenac, Aceclofenac may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M01AB11, acemetacin, Acemetacin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Gabapentin enacarbil.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Acetophenazine is combined with Gabapentin enacarbil.]
[V03AB37, idarucizumab, Gabapentin enacarbil may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Gabapentin enacarbil.]
[L01XG03, ixazomib, Gabapentin enacarbil may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[M04AB05, lesinurad, Gabapentin enacarbil may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Aprobarbital is combined with Gabapentin enacarbil.]
[M01AE16, alminoprofen, Alminoprofen may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[A02AB06, aloglutamol, The serum concentration of Gabapentin enacarbil can be decreased when it is combined with Aloglutamol.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Brivaracetam is combined with Gabapentin enacarbil.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Bromazepam is combined with Gabapentin enacarbil.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Gabapentin enacarbil.]
[A02AD05, aluminum magnesium silicate, The serum concentration of Gabapentin enacarbil can be decreased when it is combined with Almasilate.]
[A02AB03, aluminum phosphate, The serum concentration of Gabapentin enacarbil can be decreased when it is combined with Aluminium phosphate.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Alverine is combined with Gabapentin enacarbil.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gabapentin enacarbil.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Amineptine is combined with Gabapentin enacarbil.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Aniracetam is combined with Gabapentin enacarbil.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Gabapentin enacarbil.]
[N07BC01, buprenorphine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Gabapentin enacarbil.]
[L01XX27, arsenic trioxide, Arsenic trioxide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Gabapentin enacarbil.]
[S01GX07, azelastine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[A07EC04, balsalazide, Balsalazide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[A06AH05, naldemedine, Gabapentin enacarbil may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Gabapentin enacarbil may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, The therapeutic efficacy of Gabapentin enacarbil can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Beclamide.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Gabapentin enacarbil.]
[P01CA02, benznidazole, Gabapentin enacarbil may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J05AF06, abacavir, Abacavir may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N07XX13, valbenazine, Gabapentin enacarbil may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Safinamide is combined with Gabapentin enacarbil.]
[J01MA23, delafloxacin, Gabapentin enacarbil may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[L01BC06, capecitabine, Capecitabine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C07AB07, bisoprolol, Bisoprolol may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Gabapentin enacarbil.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N04AA11, bornaprine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Brotizolam.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Budesonide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M01AB07, bumadizone, Bumadizone may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Butobarbital is combined with Gabapentin enacarbil.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Butriptyline.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Vinylbital.]
[R06AX18, acrivastine, Gabapentin enacarbil may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[L02BB05, apalutamide, Gabapentin enacarbil may decrease the excretion rate of Apalutamide which could result in a higher serum level.]
[N03AF01, carbamazepine, Gabapentin enacarbil may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[A03AA03, camylofine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Gabapentin enacarbil.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Gabapentin enacarbil.]
[L04AA37, baricitinib, Gabapentin enacarbil may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01GB14, plazomicin, Gabapentin enacarbil may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[A16AX14, migalastat, Migalastat may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N03AX17, stiripentol, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Stiripentol.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Gabapentin enacarbil.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Gabapentin enacarbil.]
[D08AE05, chloroxylenol, Gabapentin enacarbil may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, Lornoxicam may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Gabapentin enacarbil.]
[R03BB08, revefenacin, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[A06AX05, prucalopride, Prucalopride may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[B01AC23, cilostazol, Cilostazol may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Cinitapride is combined with Gabapentin enacarbil.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Esketamine.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Brexanolone.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Gabapentin enacarbil.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Cloxazolam is combined with Gabapentin enacarbil.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Cyamemazine.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Gabapentin enacarbil.]
[N07XX11, pitolisant, Gabapentin enacarbil may decrease the excretion rate of Pitolisant which could result in a higher serum level.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Gabapentin enacarbil.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Gabapentin enacarbil.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M09AX08, golodirsen, Gabapentin enacarbil may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gabapentin enacarbil.]
[S01XA12, dexpanthenol, Gabapentin enacarbil may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Dezocine is combined with Gabapentin enacarbil.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Lumateperone is combined with Gabapentin enacarbil.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Frovatriptan is combined with Gabapentin enacarbil.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Gabapentin enacarbil.]
[R02AA03, dichlorobenzyl alcohol, Gabapentin enacarbil may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Gabapentin enacarbil may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Difenoxin is combined with Gabapentin enacarbil.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Gabapentin enacarbil.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Gabapentin enacarbil.]
[M01AH02, rofecoxib, Rofecoxib may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C08CA16, clevidipine, Clevidipine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Valpromide is combined with Gabapentin enacarbil.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Gabapentin enacarbil.]
[A03AA08, dihexyverine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[G04BD09, trospium, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, Droxicam may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[V08CA05, mangafodipir, Mangafodipir may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Clomethiazole is combined with Gabapentin enacarbil.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Chlormezanone is combined with Gabapentin enacarbil.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Gabapentin enacarbil.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Remimazolam.]
[N07XX04, sodium oxybate, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Gabapentin enacarbil is combined with Oliceridine.]
[P01BA01, chloroquine, Chloroquine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Gabapentin enacarbil.]
[N05AA01, chlorpromazine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.]
[A10BB02, chlorpropamide, Chlorpropamide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05AF03, chlorprothixene, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Gabapentin enacarbil.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Etifoxine.]
[N02BA07, ethenzamide, Ethenzamide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N02BA03, choline salicylate, Gabapentin enacarbil may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Gabapentin enacarbil.]
[M01AB08, etodolac, Etodolac may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M02AA06, etofenamate, Etofenamate may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M01AX25, chondroitin sulfates, Gabapentin enacarbil may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Felbamate is combined with Gabapentin enacarbil.]
[M01AE05, fenbufen, Fenbufen may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C01CA19, fenoldopam, Fenoldopam may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[S02BA08, fluocinolone acetonide, Fluocinolone acetonide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N02BG07, flupirtine, Flupirtine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Trichloroethylene.]
[A02BA01, cimetidine, Cimetidine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[S03AA07, ciprofloxacin, Ciprofloxacin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[L01XA01, cisplatin, Gabapentin enacarbil may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Citalopram.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AB03, ioflupane I-123, Ioflupane I-123 may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Gabapentin enacarbil may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Gabapentin enacarbil may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Gabapentin enacarbil.]
[M01AG01, mefenamic acid, Mefenamic acid may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when St. John's Wort is combined with Gabapentin enacarbil.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Gabapentin enacarbil.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Gabapentin enacarbil.]
[N06AA04, clomipramine, The risk or severity of adverse effects can be increased when Clomipramine is combined with Gabapentin enacarbil.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Clonazepam is combined with Gabapentin enacarbil.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Gabapentin enacarbil.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Clotiazepam is combined with Gabapentin enacarbil.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Ondansetron is combined with Gabapentin enacarbil.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Gabapentin enacarbil.]
[N05AH02, clozapine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Clozapine.]
[J01GB12, arbekacin, Gabapentin enacarbil may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Gabapentin enacarbil.]
[S02DA02, cocaine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, Gabapentin enacarbil may increase the sedative activities of Metyrosine.]
[M01AX13, proquazone, Proquazone may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Gabapentin enacarbil.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Gabapentin enacarbil.]
[M04AC01, colchicine, Colchicine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[A03AB10, hexocyclium, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[J01XB01, colistin, Gabapentin enacarbil may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[A02AD04, hydrotalcite, The serum concentration of Gabapentin enacarbil can be decreased when it is combined with Hydrotalcite.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Desflurane is combined with Gabapentin enacarbil.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Ifenprodil.]
[A10BX03, nateglinide, Nateglinide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[B01AC10, indobufen, Indobufen may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Gabapentin enacarbil.]
[J05AB14, valganciclovir, Valganciclovir may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C05BB03, invert sugar, Gabapentin enacarbil may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Iodixanol may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[V08AB05, iopromide, Gabapentin enacarbil may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Gabapentin enacarbil may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Gabapentin enacarbil may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Gabapentin enacarbil.]
[M01AH04, parecoxib, Parecoxib may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Ketazolam is combined with Gabapentin enacarbil.]
[M01AA06, kebuzone, Kebuzone may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N03AX09, lamotrigine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[N07BC04, lofexidine, The therapeutic efficacy of Gabapentin enacarbil can be increased when used in combination with Lofexidine.]
[M01AB09, lonazolac, Lonazolac may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Lormetazepam.]
[M02AA31, loxoprofen, Loxoprofen may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C09AA03, lisinopril, Lisinopril may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[A02AD02, magaldrate, The serum concentration of Gabapentin enacarbil can be decreased when it is combined with Magaldrate.]
[A06AD01, magnesium carbonate, The serum concentration of Gabapentin enacarbil can be decreased when it is combined with Magnesium carbonate.]
[A03AA04, mebeverine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Medifoxamine.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N04AA03, methixene, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Cyclizine is combined with Gabapentin enacarbil.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Cyclobarbital.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Melperone.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Minaprine is combined with Gabapentin enacarbil.]
[S01XA18, cyclosporine, Cyclosporine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Moclobemide is combined with Gabapentin enacarbil.]
[R06AX02, cyproheptadine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[M02AA02, mofebutazone, Mofebutazone may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M01AX22, morniflumate, Morniflumate may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C03XA02, conivaptan, Conivaptan may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH05, etoricoxib, Etoricoxib may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[L01AX04, dacarbazine, Dacarbazine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Dantrolene is combined with Gabapentin enacarbil.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Deanol.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Gabapentin enacarbil.]
[M01AX01, nabumetone, Nabumetone may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N07BB05, nalmefene, Nalmefene may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Nordazepam.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Niaprazine.]
[C01DX16, nicorandil, Gabapentin enacarbil may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Gabapentin enacarbil.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Gabapentin enacarbil.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Normethadone.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Escitalopram.]
[G04BD08, solifenacin, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, Olsalazine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N06AA01, desipramine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[V04CH02, indigo carmine, Gabapentin enacarbil may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M01AE12, oxaprozin, Oxaprozin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Gabapentin enacarbil.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Oxiracetam.]
[N04AA08, dexetimide, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AA01, oxyphencyclimine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Gabapentin enacarbil.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Gabapentin enacarbil.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Dextromoramide is combined with Gabapentin enacarbil.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Paroxetine.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Diamorphine is combined with Gabapentin enacarbil.]
[C01DA05, pentaerythritol tetranitrate, Pentaerythritol tetranitrate may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[P03AC04, permethrin, Permethrin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Gabapentin enacarbil.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Phenacemide is combined with Gabapentin enacarbil.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Gabapentin enacarbil.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Gabapentin enacarbil.]
[R05DA08, pholcodine, Gabapentin enacarbil may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, Diclofenac may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[A03AA07, dicyclomine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Pipamperone.]
[A03AB14, pipenzolate, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Diethylpropion is combined with Gabapentin enacarbil.]
[C08CA03, isradipine, Isradipine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[D07XC04, diflucortolone, Gabapentin enacarbil may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A03AB11, poldine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, Diflunisal may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C01AA05, digoxin, Gabapentin enacarbil may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Gabapentin enacarbil.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Gabapentin enacarbil.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J05AE08, atazanavir, Atazanavir may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[H03BC01, potassium perchlorate, Gabapentin enacarbil may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Pramocaine.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Gabapentin enacarbil.]
[V03AB09, dimercaprol, Dimercaprol may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Pridinol.]
[R06AB03, dimethindene, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[M02AX03, dimethyl sulfoxide, Dimethyl sulfoxide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Gabapentin enacarbil.]
[N02BB04, propyphenazone, Propyphenazone may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M01AB14, proglumetacin, Proglumetacin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[R06AA02, diphenhydramine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Gabapentin enacarbil.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Quazepam is combined with Gabapentin enacarbil.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Gabapentin enacarbil.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of adverse effects can be increased when Cisapride is combined with Gabapentin enacarbil.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Gabapentin enacarbil.]
[S01AX06, resorcinol, Gabapentin enacarbil may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Gabapentin enacarbil.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Risperidone is combined with Gabapentin enacarbil.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Levocetirizine is combined with Gabapentin enacarbil.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Gabapentin enacarbil.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE08, tadalafil, Tadalafil may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[S01BC05, ketorolac, Ketorolac may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C01EB18, ranolazine, Ranolazine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N02BA06, salsalate, Salsalate may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C01CA07, dobutamine, Dobutamine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C01CA04, dopamine, Dopamine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N06AA16, dothiepin, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.]
[N06AA12, doxepin, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin enacarbil.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Sevoflurane is combined with Gabapentin enacarbil.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Gabapentin enacarbil.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Sibutramine.]
[A12CA02, sodium sulfate, Gabapentin enacarbil may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Gabapentin enacarbil.]
[V04CX07, edrophonium, Edrophonium may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[L01AX03, temozolomide, Temozolomide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M01AC02, tenoxicam, Tenoxicam may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Thiopropazate.]
[G04BD01, emepronium, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Tianeptine.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Tofisopam is combined with Gabapentin enacarbil.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Toloxatone.]
[N06BA09, atomoxetine, Atomoxetine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Gabapentin enacarbil.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Gabapentin enacarbil.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Triclofos is combined with Gabapentin enacarbil.]
[A03AB08, tridihexethyl, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Gabapentin enacarbil.]
[N04AA12, tropatepine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Gabapentin enacarbil.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Urapidil.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Veralipride.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Gabapentin enacarbil.]
[N06AX16, venlafaxine, The risk or severity of adverse effects can be increased when Venlafaxine is combined with Gabapentin enacarbil.]
[N05CF02, zolpidem, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, Zomepirac may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Zonisamide is combined with Gabapentin enacarbil.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Zotepine.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Gabapentin enacarbil.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Moricizine is combined with Gabapentin enacarbil.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Ergometrine is combined with Gabapentin enacarbil.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Gabapentin enacarbil.]
[N02CA02, ergotamine, The risk or severity of adverse effects can be increased when Ergotamine is combined with Gabapentin enacarbil.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Gabapentin enacarbil.]
[L03AX05, pidotimod, Gabapentin enacarbil may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Estazolam is combined with Gabapentin enacarbil.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[G03CA03, estradiol, Estradiol may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Gabapentin enacarbil.]
[C01BD05, ibutilide, Ibutilide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N04AA05, profenamine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Gabapentin enacarbil.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Gabapentin enacarbil.]
[M01AC06, meloxicam, Meloxicam may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Gabapentin enacarbil.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Gabapentin enacarbil.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Sertindole is combined with Gabapentin enacarbil.]
[L04AD02, tacrolimus, Tacrolimus may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[R06AX12, terfenadine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Terfenadine.]
[P01AX07, trimetrexate, Trimetrexate may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Bupropion is combined with Gabapentin enacarbil.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Fluvoxamine.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Gabapentin enacarbil may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Gabapentin enacarbil may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N03AX26, fenfluramine, The risk or severity of adverse effects can be increased when Fenfluramine is combined with Gabapentin enacarbil.]
[M01AE04, fenoprofen, Fenoprofen may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Fentanyl is combined with Gabapentin enacarbil.]
[R03CC02, albuterol, Salbutamol may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[L01BB06, clofarabine, Clofarabine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[G04BD02, flavoxate, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[N02BG04, floctafenine, Floctafenine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J02AC01, fluconazole, Fluconazole may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J02AX01, flucytosine, Flucytosine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[V03AB25, flumazenil, Flumazenil may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Flunarizine is combined with Gabapentin enacarbil.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Gabapentin enacarbil.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Melitracen.]
[V03AZ01, ethanol, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N06AB03, fluoxetine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AF01, flupenthixol, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Gabapentin enacarbil.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Gabapentin enacarbil.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Fluspirilene is combined with Gabapentin enacarbil.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[L01BC03, tegafur, Gabapentin enacarbil may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Furazolidone is combined with Gabapentin enacarbil.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Gabapentin enacarbil is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Amisulpride is combined with Gabapentin enacarbil.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Gallamine.]
[S01AD09, ganciclovir, Ganciclovir may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Bifemelane.]
[C10AB04, gemfibrozil, Gemfibrozil may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01XA03, telavancin, Telavancin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be increased when Cabergoline is combined with Gabapentin enacarbil.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Methsuximide is combined with Gabapentin enacarbil.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Gabapentin enacarbil.]
[A10BB07, glipizide, Glipizide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Gabapentin enacarbil.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Glutethimide is combined with Gabapentin enacarbil.]
[L01EX02, sorafenib, Sorafenib may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M01CB04, aurothioglucose, Gabapentin enacarbil may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Pegaptanib may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C09AA09, fosinopril, Fosinopril may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[S01EX01, guanethidine, Guanethidine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Gabapentin enacarbil.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Gabapentin enacarbil.]
[N05AH04, quetiapine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N06BX13, idebenone, Gabapentin enacarbil may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Allobarbital.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[G03DC01, allylestrenol, Allylestrenol may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[A07EC02, mesalamine, Mesalazine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Hexobarbital is combined with Gabapentin enacarbil.]
[M02AA26, nimesulide, Nimesulide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C09AA04, perindopril, Perindopril may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C02DB02, hydralazine, Hydralazine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[R05DA03, hydrocodone, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Gabapentin enacarbil may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[G04BD06, propiverine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Prothipendyl.]
[B05AA07, hetastarch, Gabapentin enacarbil may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin enacarbil.]
[R02AX02, ibuprofen, Ibuprofen may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[B05XA08, sodium acetate, Gabapentin enacarbil may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01AA06, ifosfamide, Ifosfamide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Gabapentin enacarbil.]
[N06AA02, imipramine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Imipramine.]
[R01AD07, tixocortol, Gabapentin enacarbil may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Gabapentin enacarbil.]
[L01CE01, topotecan, Topotecan may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C03BA11, indapamide, Indapamide may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, Indomethacin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[A11HA07, inositol, Gabapentin enacarbil may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Milnacipran.]
[A03AA30, piperidolate, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[S01XA28, varenicline, Varenicline may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Articaine.]
[A10BH01, sitagliptin, Sitagliptin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Gabapentin enacarbil.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Gabapentin enacarbil.]
[R06AE01, buclizine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Alprenolol is combined with Gabapentin enacarbil.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, Gabapentin enacarbil may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Iproniazid is combined with Gabapentin enacarbil.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Gabapentin enacarbil.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Gabapentin enacarbil.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Gabapentin enacarbil.]
[J04AC01, isoniazid, Isoniazid may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J05AX05, inosine pranobex, Gabapentin enacarbil may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[C01DA14, isosorbide mononitrate, Isosorbide mononitrate may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Gabapentin enacarbil.]
[S01AA24, kanamycin, Gabapentin enacarbil may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[A02AB01, aluminum hydroxide, The serum concentration of Gabapentin enacarbil can be decreased when it is combined with Aluminum hydroxide.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Ketamine is combined with Gabapentin enacarbil.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Ketanserin.]
[B01AC22, prasugrel, Prasugrel may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05AH03, olanzapine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[M02AA10, ketoprofen, Ketoprofen may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N04BC09, rotigotine, Gabapentin enacarbil may increase the sedative activities of Rotigotine.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C07AG01, labetalol, Labetalol may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N04BB01, amantadine, Amantadine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[A06AX03, lubiprostone, Lubiprostone may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Lacosamide is combined with Gabapentin enacarbil.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Levodopa is combined with Gabapentin enacarbil.]
[S02DA01, lidocaine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Gabapentin enacarbil.]
[S01AA21, amikacin, Gabapentin enacarbil may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Lisuride is combined with Gabapentin enacarbil.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Lofepramine.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Gabapentin enacarbil.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Gabapentin enacarbil.]
[B05XA11, magnesium chloride, Gabapentin enacarbil may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, The serum concentration of Gabapentin enacarbil can be decreased when it is combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The serum concentration of Gabapentin enacarbil can be decreased when it is combined with Magnesium oxide.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Gabapentin enacarbil can be increased when used in combination with Magnesium sulfate.]
[L01BA05, pralatrexate, Pralatrexate may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Gabapentin enacarbil.]
[C02BB01, mecamylamine, Mecamylamine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Gabapentin enacarbil.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Medazepam.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Melatonin is combined with Gabapentin enacarbil.]
[N06DX01, memantine, Memantine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Gabapentin enacarbil.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Gabapentin enacarbil.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Gabapentin enacarbil.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Mepivacaine is combined with Gabapentin enacarbil.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Gabapentin enacarbil.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Meptazinol.]
[G04BX16, tiopronin, Tiopronin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Mesoridazine is combined with Gabapentin enacarbil.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Paliperidone is combined with Gabapentin enacarbil.]
[A10BA02, metformin, Metformin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Gabapentin enacarbil.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Gabapentin enacarbil.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Metamfetamine is combined with Gabapentin enacarbil.]
[A03AB07, methantheline, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Methapyrilene is combined with Gabapentin enacarbil.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Methaqualone is combined with Gabapentin enacarbil.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Gabapentin enacarbil.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Metergoline.]
[H03BB02, methimazole, Methimazole may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[L01BA04, pemetrexed, Gabapentin enacarbil may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Gabapentin enacarbil.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Gabapentin enacarbil.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Ziconotide is combined with Gabapentin enacarbil.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05AA02, methotrimeprazine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Gabapentin enacarbil.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, Methyldopa may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[V04CG05, methylene blue, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Methylene blue.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Gabapentin enacarbil.]
[G03EK01, methyltestosterone, Methyltestosterone may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Methyprylon is combined with Gabapentin enacarbil.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Gabapentin enacarbil.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Gabapentin enacarbil.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Metoprolol may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[V04CD01, metyrapone, Metyrapone may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Mianserin is combined with Gabapentin enacarbil.]
[N02BB03, aminopyrine, Aminophenazone may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Gabapentin enacarbil.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Gabapentin enacarbil.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Molindone is combined with Gabapentin enacarbil.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N06AA09, amitriptyline, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Gabapentin enacarbil.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Gabapentin enacarbil.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[L04AB05, certolizumab pegol, Gabapentin enacarbil may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.]
[G04BA01, ammonium chloride, Ammonium chloride may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[L04AA06, mycophenolic acid, Mycophenolic acid may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Vecuronium is combined with Gabapentin enacarbil.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Amobarbital is combined with Gabapentin enacarbil.]
[R03BB01, ipratropium bromide, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA17, amoxapine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.]
[N03AB05, fosphenytoin, The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Gabapentin enacarbil.]
[C07AA12, nadolol, Nadolol may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01CA04, amoxicillin, Amoxicillin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N04BC04, ropinirole, Gabapentin enacarbil may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Nalbuphine is combined with Gabapentin enacarbil.]
[V03AB15, naloxone, Naloxone may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N06BA01, amphetamine, Amphetamine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M02AA12, naproxen, Naproxen may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Gabapentin enacarbil.]
[S03AA01, neomycin, Gabapentin enacarbil may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Gabapentin enacarbil.]
[B01AC17, tirofiban, Tirofiban may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Iloperidone is combined with Gabapentin enacarbil.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[L03AX16, plerixafor, Plerixafor may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[S01AA23, netilmicin, Gabapentin enacarbil may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Desvenlafaxine.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C01CE01, inamrinone, Amrinone may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Nialamide is combined with Gabapentin enacarbil.]
[C08CA04, nicardipine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.]
[C08CA05, nifedipine, Nifedipine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M02AA17, niflumic acid, Niflumic acid may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C08CA07, nisoldipine, Nisoldipine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Nitrazepam is combined with Gabapentin enacarbil.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Gabapentin enacarbil.]
[N04BC05, pramipexole, Gabapentin enacarbil may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Nitroprusside may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Gabapentin enacarbil.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Nomifensine is combined with Gabapentin enacarbil.]
[N06AA10, nortriptyline, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Opium.]
[G04CA02, tamsulosin, Tamsulosin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Gabapentin enacarbil.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Gabapentin enacarbil.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Gabapentin enacarbil.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Oxymorphone is combined with Gabapentin enacarbil.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[A03AB03, oxyphenonium, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Asenapine is combined with Gabapentin enacarbil.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Gabapentin enacarbil.]
[M03AC01, pancuronium, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[J04AB30, capreomycin, Gabapentin enacarbil may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[N05CC05, paraldehyde, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Pargyline is combined with Gabapentin enacarbil.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[G04BD11, fesoterodine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Penbutolol is combined with Gabapentin enacarbil.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Penfluridol.]
[J01CE09, penicillin G procaine, Gabapentin enacarbil may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Gabapentin enacarbil.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be increased when Pentobarbital is combined with Gabapentin enacarbil.]
[L01XX08, pentostatin, Gabapentin enacarbil may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Pentoxifylline may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Pergolide is combined with Gabapentin enacarbil.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Gabapentin enacarbil.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Phenazocine.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Phenelzine is combined with Gabapentin enacarbil.]
[N03AA02, phenobarbital, The risk or severity of adverse effects can be increased when Phenobarbital is combined with Gabapentin enacarbil.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Phenoperidine.]
[V03AB36, phentolamine, Phentolamine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[M02AA01, phenylbutazone, Phenylbutazone may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N03AB02, phenytoin, The risk or severity of adverse effects can be increased when Phenytoin is combined with Gabapentin enacarbil.]
[S01AE05, levofloxacin, Levofloxacin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[B02BA01, vitamin K1, Phylloquinone may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05AG02, pimozide, The risk or severity of adverse effects can be increased when Pimozide is combined with Gabapentin enacarbil.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Pindolol is combined with Gabapentin enacarbil.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Pipotiazine is combined with Gabapentin enacarbil.]
[N06BX03, piracetam, Gabapentin enacarbil may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[A02BX03, pirenzepine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Piritramide.]
[S01BC06, piroxicam, Piroxicam may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N02CX01, pizotyline, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Proxibarbal.]
[A10BG02, rosiglitazone, Rosiglitazone may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Alosetron is combined with Gabapentin enacarbil.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH03, saxagliptin, Saxagliptin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Prazepam is combined with Gabapentin enacarbil.]
[H02AB07, prednisone, Prednisone may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Gabapentin enacarbil.]
[N03AA03, primidone, The risk or severity of adverse effects can be increased when Primidone is combined with Gabapentin enacarbil.]
[M04AB01, probenecid, Probenecid may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C01BA02, procainamide, Gabapentin enacarbil may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Procaine is combined with Gabapentin enacarbil.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Gabapentin enacarbil.]
[C10AB05, fenofibrate, Fenofibrate may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gabapentin enacarbil.]
[N04AA04, procyclidine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[N05AA03, promazine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Propanidid.]
[A03AB05, propantheline, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Periciazine is combined with Gabapentin enacarbil.]
[N05CM06, propiomazine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Gabapentin enacarbil.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Gabapentin enacarbil.]
[C07AA05, propranolol, Propranolol may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Gabapentin enacarbil.]
[B01AC09, epoprostenol, Epoprostenol may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Gabapentin enacarbil.]
[N05AX12, aripiprazole, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[N07XX07, dalfampridine, Dalfampridine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[A03AB15, diphemanil, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Gabapentin enacarbil.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Pyrantel.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Mepyramine is combined with Gabapentin enacarbil.]
[C01BA01, quinidine, Gabapentin enacarbil may decrease the excretion rate of Quinidine which could result in a higher serum level.]
[P01BC01, quinine, The risk or severity of adverse effects can be increased when Quinine is combined with Gabapentin enacarbil.]
[A02BA02, ranitidine, Ranitidine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Gabapentin enacarbil.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Oxitriptan is combined with Gabapentin enacarbil.]
[N02BA05, salicylamide, Salicylamide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[A07EC01, sulfasalazine, Sulfasalazine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[S01BC08, salicylic acid, Salicylic acid may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[S01FA02, scopolamine, Gabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Gabapentin enacarbil.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Selegiline is combined with Gabapentin enacarbil.]
[J01GB08, sisomicin, Gabapentin enacarbil may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Gabapentin enacarbil may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Sorbitol may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Gabapentin enacarbil which could result in a lower serum level and potentially a reduction in efficacy.]
[G03XB02, ulipristal, The metabolism of Ulipristal can be increased when combined with Gabapentin.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Gabapentin.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Sulpiride is combined with Gabapentin.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Gabapentin is combined with Sulthiame.]
[L01BB02, mercaptopurine, Gabapentin may increase the excretion rate of Mercaptopurine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Gabapentin.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Gabapentin is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Gabapentin.]
[L04AX02, thalidomide, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, Gabapentin may increase the excretion rate of Theobromine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, Gabapentin may increase the excretion rate of Theophylline which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Gabapentin.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Thiopental is combined with Gabapentin.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Thioridazine is combined with Gabapentin.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Gabapentin is combined with Thiothixene.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Gabapentin is combined with Tiapride.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Tilidine.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Gabapentin is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of CNS depression can be increased when Gabapentin is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Gabapentin.]
[N06AX05, trazodone, The risk or severity of adverse effects can be increased when Gabapentin is combined with Trazodone.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Gabapentin.]
[A03AB12, mepenzolate, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Gabapentin.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Gabapentin is combined with Trifluperidol.]
[N05AA05, triflupromazine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Gabapentin.]
[N06AA06, trimipramine, The risk or severity of adverse effects can be increased when Trimipramine is combined with Gabapentin.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Gabapentin.]
[A03BB01, butylscopolamine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Gabapentin is combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Gabapentin.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Tubocurarine.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Ezogabine.]
[N06AX09, viloxazine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Viloxazine.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Gabapentin is combined with Zuclopenthixol.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Gabapentin is combined with Levetiracetam.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Gabapentin is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be increased when combined with Gabapentin.]
[G04BD07, tolterodine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Gabapentin is combined with Atracurium.]
[S01FA01, atropine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[J01CA09, azlocillin, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Azlocillin.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Lorcaserin.]
[A02AA05, magnesium silicate, The bioavailability of Gabapentin can be decreased when combined with Magnesium silicate.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Gabapentin is combined with Barbital.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Gabapentin is combined with Rasagiline.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Gabapentin is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Gabapentin.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Gabapentin.]
[R06AC06, thonzylamine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Gabapentin is combined with Diethyl ether.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Gabapentin is combined with Pomalidomide.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Gabapentin is combined with Benperidol.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Benzocaine.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Gabapentin.]
[N04AC01, benztropine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Gabapentin is combined with Levomilnacipran.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Vortioxetine.]
[G03AC08, etonogestrel, The metabolism of Etonogestrel can be increased when combined with Gabapentin.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Eslicarbazepine.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Vigabatrin.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Gabapentin is combined with Tasimelteon.]
[A16AA06, betaine, The therapeutic efficacy of Betaine can be decreased when used in combination with Gabapentin.]
[A03BA03, hyoscyamine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Gabapentin is combined with Alfaxalone.]
[D11AA01, glycopyrronium, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Acepromazine.]
[N04AA02, biperiden, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[N06AX11, mirtazapine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[A03AA09, difemerine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Gabapentin is combined with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Flibanserin.]
[A06AD03, magnesium peroxide, The bioavailability of Gabapentin can be decreased when combined with Magnesium peroxide.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Cariprazine.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Gabapentin.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Acetophenazine.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Gabapentin.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Gabapentin is combined with Aprobarbital.]
[A02AB06, aloglutamol, The bioavailability of Gabapentin can be decreased when combined with Aloglutamol.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Gabapentin is combined with Brivaracetam.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Gabapentin is combined with Bromazepam.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, The bioavailability of Gabapentin can be decreased when combined with Almasilate.]
[A02AB03, aluminum phosphate, The bioavailability of Gabapentin can be decreased when combined with Aluminium phosphate.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gabapentin.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Amineptine.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Gabapentin is combined with Aniracetam.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Bupivacaine.]
[N07BC01, buprenorphine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Gabapentin.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Gabapentin.]
[R06AX09, azatadine, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Azatadine.]
[S01GX07, azelastine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[R03DA08, bamifylline, Gabapentin may increase the excretion rate of Bamifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BF02, pregabalin, The therapeutic efficacy of Gabapentin can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Gabapentin is combined with Beclamide.]
[N06BC01, caffeine, Gabapentin may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Oxybuprocaine.]
[J01XX08, linezolid, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Linezolid.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Gabapentin is combined with Safinamide.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Gabapentin.]
[N04AA11, bornaprine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Gabapentin is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Gabapentin is combined with Brotizolam.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Gabapentin is combined with Butobarbital.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Gabapentin is combined with Butriptyline.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Capsaicin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Gabapentin is combined with Vinylbital.]
[N03AF01, carbamazepine, Carbamazepine may increase the Change in thyroid function activities of Gabapentin.]
[A03AA03, camylofine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Gabapentin.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Gabapentin.]
[N03AX17, stiripentol, The risk or severity of adverse effects can be increased when Gabapentin is combined with Stiripentol.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Gabapentin.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Gabapentin is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[R03DA02, oxtriphylline, Gabapentin may increase the excretion rate of Oxtriphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Gabapentin.]
[R03BB08, revefenacin, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Gabapentin is combined with Cinitapride.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Esketamine.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Gabapentin is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Gabapentin is combined with Brexanolone.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Gabapentin.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Gabapentin is combined with Cloxazolam.]
[J01DD01, cefotaxime, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Cefotaxime.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Cyamemazine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Gabapentin.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Yohimbine.]
[J01DB03, cephalothin, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Cefalotin.]
[G03DB05, demegestone, The metabolism of Demegestone can be increased when combined with Gabapentin.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Gabapentin.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be increased when combined with Gabapentin.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gabapentin.]
[R06AB02, dexchlorpheniramine, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Dexchlorpheniramine.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Dezocine.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Gabapentin is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Gabapentin is combined with Lumateperone.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Gabapentin is combined with Frovatriptan.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Gabapentin is combined with Dichloralphenazone.]
[G03DB08, dienogest, The metabolism of Dienogest can be increased when combined with Gabapentin.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Gabapentin.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Gabapentin is combined with Valpromide.]
[L01AA02, chlorambucil, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Chlorambucil.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Gabapentin.]
[A03AA08, dihexyverine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[G04BD09, trospium, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Gabapentin is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Gabapentin is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Dyclonine.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Gabapentin is combined with Remimazolam.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Gabapentin is combined with Oliceridine.]
[P01BA01, chloroquine, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Chloroquine.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.]
[N05AF03, chlorprothixene, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Gabapentin.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Etifoxine.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Gabapentin is combined with Ethyl loflazepate.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be increased when combined with Gabapentin.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Gabapentin is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Felbamate is combined with Gabapentin.]
[N06BA10, fenethylline, Gabapentin may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Gabapentin is combined with Trichloroethylene.]
[N07XX04, sodium oxybate, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Gabapentin is combined with Citalopram.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Gabapentin.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when Gabapentin is combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Gabapentin.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Levobupivacaine.]
[N06AA04, clomipramine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Clomipramine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Gabapentin is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Gabapentin.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Gabapentin is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Ondansetron is combined with Gabapentin.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Gabapentin.]
[N05AH02, clozapine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Clozapine.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Gabapentin.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Cocaine.]
[C02KB01, metyrosine, Gabapentin may increase the sedative activities of Metyrosine.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Gabapentin.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Gabapentin.]
[A03AB10, hexocyclium, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[A02AD04, hydrotalcite, The bioavailability of Gabapentin can be decreased when combined with Hydrotalcite.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Gabapentin is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Gabapentin is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Gabapentin is combined with Ifenprodil.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Gabapentin.]
[J05AB14, valganciclovir, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Valganciclovir.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Gabapentin.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Gabapentin is combined with Ketazolam.]
[N03AX09, lamotrigine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[N07BC04, lofexidine, The therapeutic efficacy of Gabapentin can be increased when used in combination with Lofexidine.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Gabapentin is combined with Lormetazepam.]
[H01AA02, cosyntropin, The risk or severity of liver damage can be increased when Tetracosactide is combined with Gabapentin.]
[A02AD02, magaldrate, The bioavailability of Gabapentin can be decreased when combined with Magaldrate.]
[A06AD01, magnesium carbonate, The bioavailability of Gabapentin can be decreased when combined with Magnesium carbonate.]
[A03AA04, mebeverine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Medifoxamine.]
[R06AD04, methdilazine, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Methdilazine.]
[N04AA03, methixene, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Gabapentin is combined with Cyclobarbital.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Gabapentin is combined with Melperone.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Minaprine is combined with Gabapentin.]
[S01XA18, cyclosporine, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Gabapentin is combined with Moclobemide.]
[R06AX02, cyproheptadine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Gabapentin is combined with Dantrolene.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Gabapentin is combined with Deanol.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Gabapentin is combined with Nordazepam.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Gabapentin is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Niaprazine.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Gabapentin.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be increased when combined with Gabapentin.]
[C01CA23, theodrenaline, Gabapentin may increase the excretion rate of Theodrenaline which could result in a lower serum level and potentially a reduction in efficacy.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Gabapentin.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Gabapentin is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Gabapentin is combined with Escitalopram.]
[G04BD08, solifenacin, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[N06AA01, desipramine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Gabapentin.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Gabapentin is combined with Oxiracetam.]
[N04AA08, dexetimide, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AA01, oxyphencyclimine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Amphetamine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Gabapentin.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Gabapentin.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Gabapentin is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Paroxetine.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Diamorphine.]
[C04AD01, pentifylline, Gabapentin may increase the excretion rate of Pentifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Gabapentin.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Gabapentin is combined with Phenacemide.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Phenol.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Gabapentin.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Cinchocaine.]
[A03AA07, dicyclomine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Gabapentin is combined with Pipamperone.]
[A03AB14, pipenzolate, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Diethylpropion is combined with Gabapentin.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be increased when combined with Gabapentin.]
[A03AB11, poldine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Gabapentin.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Gabapentin.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Pramocaine.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Gabapentin.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Gabapentin is combined with Pridinol.]
[R06AB03, dimethindene, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Gabapentin.]
[N06BC02, propentofylline, Gabapentin may increase the excretion rate of Propentofylline which could result in a lower serum level and potentially a reduction in efficacy.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Proparacaine.]
[R03DA03, proxyphylline, Gabapentin may increase the excretion rate of Proxyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Gabapentin is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Gabapentin is combined with Quazepam.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Gabapentin is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of adverse effects can be increased when Cisapride is combined with Gabapentin.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Gabapentin.]
[C01BA03, disopyramide, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[P03AA04, disulfiram, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Disulfiram.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Gabapentin.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Risperidone is combined with Gabapentin.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Ropivacaine.]
[N06AA16, dothiepin, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.]
[N06AA12, doxepin, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Gabapentin is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Gabapentin is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Sibutramine.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Sodium phosphate, monobasic.]
[R03DA01, dyphylline, Gabapentin may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Gabapentin is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Gabapentin.]
[A08AB01, orlistat, Orlistat can cause a decrease in the absorption of Gabapentin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Gabapentin is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Gabapentin is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Gabapentin is combined with Thiopropazate.]
[G04BD01, emepronium, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Tianeptine.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Gabapentin is combined with Tofisopam.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Gabapentin is combined with Toloxatone.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Gabapentin.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Gabapentin is combined with Loprazolam.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Gabapentin is combined with Triclofos.]
[A03AB08, tridihexethyl, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Gabapentin.]
[N04AA12, tropatepine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Gabapentin.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Gabapentin is combined with Urapidil.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Gabapentin is combined with Veralipride.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Gabapentin.]
[N06AX16, venlafaxine, The risk or severity of adverse effects can be increased when Venlafaxine is combined with Gabapentin.]
[N05CF02, zolpidem, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Zonisamide is combined with Gabapentin.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Gabapentin is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Zotepine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Guanfacine.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Moricizine is combined with Gabapentin.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Gabapentin is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The risk or severity of adverse effects can be increased when Ergotamine is combined with Gabapentin.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Gabapentin is combined with Estazolam.]
[G03CA03, estradiol, The metabolism of Estradiol can be increased when combined with Gabapentin.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Gabapentin.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be increased when combined with Gabapentin.]
[N04AA05, profenamine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Gabapentin.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Gabapentin.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Meloxicam.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Ethylmorphine.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Etidocaine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Gabapentin.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Gabapentin is combined with Sertindole.]
[R06AX12, terfenadine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Terfenadine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Gabapentin is combined with Bupropion.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Fluvoxamine.]
[N03AX26, fenfluramine, The risk or severity of adverse effects can be increased when Fenfluramine is combined with Gabapentin.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Fentanyl is combined with Gabapentin.]
[G04BD02, flavoxate, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Gabapentin is combined with Flunitrazepam.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Gabapentin is combined with Melitracen.]
[V03AZ01, ethanol, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[N06AB03, fluoxetine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AF01, flupenthixol, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Gabapentin.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Gabapentin.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Gabapentin is combined with Fluspirilene.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Gabapentin is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Furazolidone is combined with Gabapentin.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Gabapentin is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Gabapentin is combined with Amisulpride.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Gallamine.]
[S01AD09, ganciclovir, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Ganciclovir.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Gabapentin is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Gabapentin is combined with Bifemelane.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be increased when Cabergoline is combined with Gabapentin.]
[C01CA21, cafedrine, Gabapentin may increase the excretion rate of Cafedrine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Gabapentin is combined with Methsuximide.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be increased when combined with Gabapentin.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Gabapentin.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Gabapentin.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Gabapentin is combined with Glutethimide.]
[P01BX01, halofantrine, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Gabapentin.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Gabapentin is combined with Halothane.]
[N05AH04, quetiapine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Gabapentin is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Gabapentin is combined with Allobarbital.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Gabapentin is combined with Hexobarbital.]
[R05DA03, hydrocodone, The serum concentration of Hydrocodone can be decreased when it is combined with Gabapentin.]
[G04BD06, propiverine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Hydroxychloroquine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Gabapentin is combined with Prothipendyl.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Gabapentin.]
[N06AA02, imipramine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Imipramine.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Gabapentin.]
[L01CE01, topotecan, Gabapentin may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Gabapentin is combined with Milnacipran.]
[A03AA30, piperidolate, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Articaine.]
[V08AB02, iohexol, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Iohexol.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Gabapentin.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Gabapentin.]
[R06AE01, buclizine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Alprenolol is combined with Gabapentin.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Gabapentin is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Gabapentin is combined with Iproniazid.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Gabapentin is combined with Isocarboxazid.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Gabapentin.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Gabapentin.]
[J04AC01, isoniazid, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Isoniazid.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Gabapentin.]
[A02AB01, aluminum hydroxide, The bioavailability of Gabapentin can be decreased when combined with Aluminum hydroxide.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Ketanserin.]
[N05AH03, olanzapine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[N04BC09, rotigotine, Gabapentin may increase the sedative activities of Rotigotine.]
[J01MB02, nalidixic acid, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Nalidixic acid.]
[D11AX02, gamma-linolenic acid, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Gamolenic acid.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Gabapentin is combined with Lacosamide.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be increased when combined with Gabapentin.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Gabapentin is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Lidocaine.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Lisuride is combined with Gabapentin.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Lofepramine.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Gabapentin.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Gabapentin.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be increased when combined with Gabapentin.]
[G04BX01, magnesium hydroxide, The bioavailability of Gabapentin can be decreased when combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The bioavailability of Gabapentin can be decreased when combined with Magnesium oxide.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Gabapentin can be increased when used in combination with Magnesium sulfate.]
[N06AA21, maprotiline, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Gabapentin.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Gabapentin.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Gabapentin is combined with Medazepam.]
[P01BC02, mefloquine, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Mefloquine.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Melatonin.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Gabapentin.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Gabapentin.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Gabapentin.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Gabapentin.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Gabapentin is combined with Meptazinol.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Mesoridazine is combined with Gabapentin.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Gabapentin is combined with Paliperidone.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Gabapentin.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Gabapentin.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Metamfetamine.]
[A03AB07, methantheline, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Gabapentin is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Gabapentin is combined with Methaqualone.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Gabapentin.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Gabapentin is combined with Metergoline.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Gabapentin.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Gabapentin.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Gabapentin is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Gabapentin is combined with Methoxyflurane.]
[V04CG05, methylene blue, The risk or severity of adverse effects can be increased when Gabapentin is combined with Methylene blue.]
[R03DA05, aminophylline, Gabapentin may increase the excretion rate of Aminophylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BA04, methylphenidate, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Methylphenidate.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Gabapentin.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Gabapentin is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Gabapentin.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Gabapentin.]
[P01AB01, metronidazole, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Metronidazole.]
[N06AX03, mianserin, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Mianserin.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Gabapentin.]
[G03XB01, mifepristone, The metabolism of Mifepristone can be increased when combined with Gabapentin.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Gabapentin is combined with Molindone.]
[N06AA09, amitriptyline, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.]
[N02AA01, morphine, The serum concentration of Gabapentin can be increased when it is combined with Morphine.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Gabapentin.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Gabapentin is combined with Vecuronium.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Gabapentin is combined with Amobarbital.]
[N06AA17, amoxapine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.]
[N03AB05, fosphenytoin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Fosphenytoin.]
[N04BC04, ropinirole, Gabapentin may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Gabapentin is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Nalbuphine is combined with Gabapentin.]
[N06BA01, amphetamine, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Amphetamine.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Gabapentin.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Gabapentin.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Gabapentin is combined with Iloperidone.]
[J02AA01, amphotericin B, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Amphotericin B.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Desvenlafaxine.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Gabapentin is combined with Nialamide.]
[C08CA04, nicardipine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Gabapentin is combined with Nitrazepam.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Gabapentin.]
[N04BC05, pramipexole, Gabapentin may increase the sedative activities of Pramipexole.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Gabapentin is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Nomifensine.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be increased when combined with Gabapentin.]
[G03AC07, norgestrienone, The metabolism of Norgestrienone can be increased when combined with Gabapentin.]
[N06AA10, nortriptyline, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Gabapentin is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Gabapentin is combined with Opium.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Gabapentin.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Gabapentin is combined with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Gabapentin.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Gabapentin is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Oxypertine.]
[A03AB03, oxyphenonium, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.]
[M03AC01, pancuronium, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be increased when combined with Gabapentin.]
[N05CC05, paraldehyde, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Gabapentin is combined with Pargyline.]
[G04BD11, fesoterodine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Gabapentin is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Gabapentin is combined with Penfluridol.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Gabapentin.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be increased when Pentobarbital is combined with Gabapentin.]
[C04AD03, pentoxifylline, Gabapentin may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Gabapentin is combined with Pergolide.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Gabapentin.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Phenazocine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Phenelzine is combined with Gabapentin.]
[N03AA02, phenobarbital, The risk or severity of adverse effects can be increased when Gabapentin is combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Phenoperidine.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Phenylpropanolamine.]
[N03AB02, phenytoin, The risk or severity of adverse effects can be increased when Phenytoin is combined with Gabapentin.]
[N05AG02, pimozide, The risk or severity of adverse effects can be increased when Gabapentin is combined with Pimozide.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Pindolol is combined with Gabapentin.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Pipotiazine.]
[A02BX03, pirenzepine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Gabapentin is combined with Piritramide.]
[N02CX01, pizotyline, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Gabapentin is combined with Proxibarbal.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Alosetron is combined with Gabapentin.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Gabapentin is combined with Prazepam.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Prilocaine.]
[N03AA03, primidone, The risk or severity of adverse effects can be increased when Primidone is combined with Gabapentin.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Procarbazine.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gabapentin.]
[N04AA04, procyclidine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Progesterone can be increased when combined with Gabapentin.]
[N05AA03, promazine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Gabapentin is combined with Propanidid.]
[A03AB05, propantheline, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Periciazine.]
[N05CM06, propiomazine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Gabapentin.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Gabapentin.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Gabapentin.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Gabapentin.]
[N05AX12, aripiprazole, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[A03AB15, diphemanil, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Gabapentin.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Gabapentin is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Gabapentin is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Gabapentin is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Gabapentin is combined with Mepyramine.]
[C01BA01, quinidine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Quinidine.]
[P01BC01, quinine, The risk or severity of adverse effects can be increased when Quinine is combined with Gabapentin.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Gabapentin.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Gabapentin is combined with Oxitriptan.]
[S01FA02, scopolamine, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Gabapentin.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Gabapentin is combined with Selegiline.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Gabapentin is combined with Chloral hydrate.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Gabapentin.]
[R03BB01, ipratropium bromide, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
